Top

Published in:

01-08-2016 | Review Article

Identifying novel therapeutic agents using xenograft models of pediatric cancer

Authors: Raushan T. Kurmasheva, Peter J. Houghton

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2016

Abstract

In the USA, the overall cure rate for all childhood cancers is seventy percent, and in many patients that ultimately fail curative therapy, initial responses to current multimodality treatments (surgery, radiation therapy and chemotherapy) is good, with overall 5-year event-free survival approaching 80 %. However, current approaches to curative therapy result in significant morbidity and long-term sequelae, including cardiac dysfunction and cognitive impairment. Furthermore, dose-intensive chemotherapy with conventional agents has not significantly improved outcomes for patients that present with advanced or metastatic disease. Classical cytotoxic agents remain the backbone for curative therapy of both hematologic and solid tumors of childhood. While ‘molecularly’ targeted agents have shown some clinical activity, responses are often modest and of short duration; hence, there is a need to identify new classes of cytotoxic agent that are effective in patients at relapse and that have reduced or different toxicity profiles to normal tissues. Here we review the pediatric preclinical testing program experience of testing novel agents, and the value and limitations of preclinical xenograft models and genetically engineered mouse models for developing novel agents for treatment of childhood cancer.

Smith MA, Altekruse SF, Adamson PC et al (2014) Declining childhood and adolescent cancer mortality. Cancer 120(16):2497–2506. doi:10.1002/cncr.28748 CrossRefPubMedPubMedCentral

Oeffinger KC, Mertens AC, Sklar CA et al (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355(15):1572–1582. doi:10.1056/NEJMsa060185 CrossRefPubMed

Donahue B (1992) Short- and long-term complications of radiation therapy for pediatric brain tumors. Pediatr Neurosurg 18(4):207–217CrossRefPubMed

Sharif S, Ferner R, Birch JM et al (2006) Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 24(16):2570–2575. doi:10.1200/JCO.2005.03.8349 CrossRefPubMed

Siu A, Wind JJ, Iorgulescu JB et al (2012) Radiation necrosis following treatment of high grade glioma—a review of the literature and current understanding. Acta Neurochir 154(2):191–201. doi:10.1007/s00701-011-1228-6 (discussion 201) CrossRefPubMed

Brandsma D, Stalpers L, Taal W et al (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9(5):453–461. doi:10.1016/S1470-2045(08)70125-6 CrossRefPubMed

Ruben JD, Dally M, Bailey M et al (2006) Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 65(2):499–508. doi:10.1016/j.ijrobp.2005.12.002 CrossRefPubMed

Houghton PJ, Stewart CF, Thompson J et al (1998) Extending principles learned in model systems to clinical trials design. Oncology 12(8 Suppl 6):84–93PubMed

Houghton PJ, Morton CL, Tucker C et al (2007) The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 49(7):928–940. doi:10.1002/pbc.21078 CrossRefPubMed

10.

Tajbakhsh M, Houghton PJ, Morton CL et al (2008) Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer 50(5):992–1000. doi:10.1002/pbc.21263 CrossRefPubMed

11.

Thompson J, George EO, Poquette CA et al (1999) Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res 5(11):3617–3631PubMed

12.

Snehalatha M, Kolachina V, Saha RN et al (2013) Enhanced tumor uptake, biodistribution and pharmacokinetics of etoposide loaded nanoparticles in Dalton’s lymphoma tumor bearing mice. J Pharm Bioallied Sci 5(4):290–297. doi:10.4103/0975-7406.120081 CrossRefPubMedPubMedCentral

13.

Arbuck SG, Douglass HO, Crom WR et al (1986) Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 4(11):1690–1695PubMed

14.

Keir ST, Maris JM, Reynolds CP et al (2013) Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer 60(5):783–790. doi:10.1002/pbc.24368 CrossRefPubMedPubMedCentral

15.

Peterson JK, Houghton PJ (2004) Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40(6):837–844. doi:10.1016/j.ejca.2004.01.003 CrossRefPubMed

16.

Leggas M, Stewart CF, Woo MH et al (2002) Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 8(9):3000–3007PubMed

17.

Wong H, Choo EF, Alicke B et al (2012) Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res 18(14):3846–3855. doi:10.1158/1078-0432.CCR-12-0738 CrossRefPubMed

18.

Hurwitz CA, Strauss LC, Kepner J et al (2001) Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. J Pediatr Hematol Oncol 23(5):277–281CrossRefPubMed

19.

Hayashi RJ, Blaney S, Sullivan J et al (2003) Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 25(7):539–542CrossRefPubMed

20.

Kretschmar CS, Kletzel M, Murray K et al (2004) Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study. J Clin Oncol 22(20):4119–4126CrossRefPubMed

21.

Reynolds CP, Kang MH, Maris JM et al (2015) Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. Pediatr Blood Cancer. doi:10.1002/pbc.25611

22.

Houghton PJ, Kurmasheva RT, Kolb EA et al (2015) Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane((R))) by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 62(7):1214–1221. doi:10.1002/pbc.25474 CrossRefPubMedPubMedCentral

23.

Kolb EA, Gorlick R, Reynolds CP et al (2013) Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 60(8):1325–1332. doi:10.1002/pbc.24517 CrossRefPubMedPubMedCentral

24.

Kolb EA, Gorlick R, Keir ST et al (2015) Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 62(6):1106–1109. doi:10.1002/pbc.25329 CrossRefPubMed

25.

Patterson AV, Ferry DM, Edmunds SJ et al (2007) Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 13(13):3922–3932. doi:10.1158/1078-0432.CCR-07-0478 CrossRefPubMed

26.

Gu Y, Guise CP, Patel K et al (2011) Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice. Cancer Chemother Pharmacol 67(3):543–555. doi:10.1007/s00280-010-1354-5 CrossRefPubMed

27.

Houghton PJ, Lock R, Carol H et al (2011) Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatr Blood Cancer 57(3):443–453. doi:10.1002/pbc.22921 CrossRefPubMed

28.

Moradi Manesh D, El-Hoss J, Evans K et al (2015) AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. Blood 126(10):1193–1202. doi:10.1182/blood-2014-12-618900 CrossRefPubMed

29.

Smith MA, Hampton OA, Reynolds CP et al (2015) Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 62(1):91–98. doi:10.1002/pbc.25201 CrossRefPubMed

30.

Choy E, Butrynski JE, Harmon DC et al (2014) Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer 14:813. doi:10.1186/1471-2407-14-813 CrossRefPubMedPubMedCentral

31.

Smith MA, Reynolds CP, Kang MH et al (2015) Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res 21(4):819–832. doi:10.1158/1078-0432.CCR-14-2572 CrossRefPubMed

32.

Maris JM, Morton CL, Gorlick R et al (2010) Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 55(1):26–34. doi:10.1002/pbc.22430 PubMedPubMedCentral

33.

Gorlick R, Kolb EA, Keir ST et al (2014) Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 61(1):158–164. doi:10.1002/pbc.24616 CrossRefPubMed

34.

Carol H, Boehm I, Reynolds CP et al (2011) Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol 68(5):1291–1304. doi:10.1007/s00280-011-1618-8 CrossRefPubMedPubMedCentral

35.

Kusafuka T, Fukuzawa M, Oue T et al (1997) Mutation analysis of p53 gene in childhood malignant solid tumors. J Pediatr Surg 32(8):1175–1180CrossRefPubMed

36.

Pollack IF, Hamilton RL, Finkelstein SD et al (1997) The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 57(2):304–309PubMed

37.

Tweddle DA, Pearson AD, Haber M et al (2003) The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 197(1–2):93–98CrossRefPubMed

38.

Oliner JD, Kinzler KW, Meltzer PS et al (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358(6381):80–83CrossRefPubMed

39.

Overholtzer M, Rao PH, Favis R et al (2003) The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci 100(20):11547–11552. doi:10.1073/pnas.1934852100 CrossRefPubMedPubMedCentral

40.

Pishas KI, Al-Ejeh F, Zinonos I et al (2011) Nutlin-3a Is a potential therapeutic for ewing sarcoma. Clin Cancer Res 17(3):494–504. doi:10.1158/1078-0432.ccr-10-1587 CrossRefPubMed

41.

Malkin D, Sexsmith E, Yeger H et al (1994) Mutations of the p53 tumor suppressor gene occur infrequently in Wilms’ Tumor. Cancer Res 54(8):2077–2079PubMed

42.

Marks D, Kurz B, Link M et al (1997) Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J Clin Oncol 15(3):1158–1162PubMed

43.

Wada M, Bartram C, Nakamura H et al (1993) Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 82(10):3163–3169PubMed

44.

Van Maerken T, Rihani A, Dreidax D et al (2011) Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol Cancer Ther 10(6):983–993. doi:10.1158/1535-7163.mct-10-1090 CrossRefPubMed

45.

Van Maerken T, Vandesompele J, Rihani A et al (2009) Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14ARF-MDM2-p53 axis. Cell Death Differ 16(12):1563–1572CrossRefPubMed

46.

Hof J, Krentz S, van Schewick C et al (2011) Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol 29(23):3185–3193. doi:10.1200/JCO.2011.34.8144 CrossRefPubMed

47.

McCubrey JA, Abrams SL, Ligresti G et al (2008) Involvement of p53 and Raf//MEK//ERK pathways in hematopoietic drug resistance. Leukemia 22(11):2080–2090CrossRefPubMed

48.

Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53 protei–protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49(1):223–241. doi:10.1146/annurev.pharmtox.48.113006.094723 CrossRefPubMedPubMedCentral

49.

Vassilev LT, Vu BT, Graves B et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659):844–848. doi:10.1126/science.1092472 CrossRefPubMed

50.

Carol H, Reynolds CP, Kang MH et al (2013) Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 60(4):633–641. doi:10.1002/pbc.24235 CrossRefPubMed

51.

Richmond J, Carol H, Evans K et al (2015) Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia. Clin Cancer Res 21(6):1395–1405. doi:10.1158/1078-0432.CCR-14-2300 CrossRefPubMedPubMedCentral

52.

Andreeff M, Kelly KR, Yee KW et al (2015) Results of the Phase 1 trial of RG7112, a small-molecule MDM2 antagonist in Leukemia. Clin Cancer Res. doi:10.1158/1078-0432.CCR-15-0481

53.

Iancu-Rubin C, Mosoyan G, Glenn K et al (2014) Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis. Exp Hematol 42(2):137–145 e135. doi:10.1016/j.exphem.2013.11.012 CrossRefPubMed

54.

Canon J, Osgood T, Olson SH et al (2015) The MDM2 Inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents. Mol Cancer Ther 14(3):649–658. doi:10.1158/1535-7163.MCT-14-0710 CrossRefPubMed

55.

Mosammaparast N, Pemberton LF (2004) Karyopherins: from nuclear-transport mediators to nuclear-function regulators. Trends Cell Biol 14(10):547–556. doi:10.1016/j.tcb.2004.09.004 CrossRefPubMed

56.

Senapedis WT, Baloglu E, Landesman Y (2014) Clinical translation of nuclear export inhibitors in cancer. Semin Cancer Biol 27C:74–86. doi:10.1016/j.semcancer.2014.04.005 CrossRef

57.

Kudo N, Matsumori N, Taoka H et al (1999) Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 96(16):9112–9117CrossRefPubMedPubMedCentral

58.

Sun Q, Carrasco YP, Hu Y et al (2013) Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci USA 110(4):1303–1308. doi:10.1073/pnas.1217203110 CrossRefPubMedPubMedCentral

59.

Wolff B, Sanglier JJ, Wang Y (1997) Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol 4(2):139–147CrossRefPubMed

60.

Neggers JE, Vercruysse T, Jacquemyn M et al (2015) Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing. Chem Biol 22(1):107–116. doi:10.1016/j.chembiol.2014.11.015 CrossRefPubMed

61.

Attiyeh EF, Maris JM, Lock R et al (2015) Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the pediatric preclinical testing program. Pediatr Blood Cancer. doi:10.1002/pbc.25727 PubMed

62.

Chai J, Du C, Wu JW et al (2000) Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406(6798):855–862. doi:10.1038/35022514 CrossRefPubMed

63.

Du C, Fang M, Li Y et al (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102(1):33–42CrossRefPubMed

64.

Liu Z, Sun C, Olejniczak ET et al (2000) Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 408(6815):1004–1008. doi:10.1038/35050006 CrossRefPubMed

65.

Srinivasula SM, Hegde R, Saleh A et al (2001) A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410(6824):112–116. doi:10.1038/35065125 CrossRefPubMed

66.

Gaither A, Porter D, Yao Y et al (2007) A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res 67(24):11493–11498. doi:10.1158/0008-5472.CAN-07-5173 CrossRefPubMed

67.

Varfolomeev E, Goncharov T, Fedorova AV et al (2008) c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 283(36):24295–24299. doi:10.1074/jbc.C800128200 CrossRefPubMedPubMedCentral

68.

Mahoney DJ, Cheung HH, Mrad RL et al (2008) Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 105(33):11778–11783. doi:10.1073/pnas.0711122105 CrossRefPubMedPubMedCentral

69.

Houghton PJ, Kang MH, Reynolds CP et al (2012) Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 58(4):636–639. doi:10.1002/pbc.23167 CrossRefPubMed

70.

Teitz T, Wei T, Valentine MB et al (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6(5):529–535. doi:10.1038/75007 CrossRefPubMed

71.

Harada K, Toyooka S, Shivapurkar N et al (2002) Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 62(20):5897–5901PubMed

72.

Fu X, Guadagni F, Hoffman RM (1992) A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci USA 89(12):5645–5649CrossRefPubMedPubMedCentral

73.

Fu XY, Besterman JM, Monosov A et al (1991) Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci USA 88(20):9345–9349CrossRefPubMedPubMedCentral

74.

Fu XY, Theodorescu D, Kerbel RS et al (1991) Extensive multi-organ metastasis following orthotopic onplantation of histologically-intact human bladder carcinoma tissue in nude mice. Int J Cancer 49(6):938–939CrossRefPubMed

75.

Loukopoulos P, Kanetaka K, Takamura M et al (2004) Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 29(3):193–203CrossRefPubMed

76.

Woods GM, Bondra K, Chronowski C et al (2015) Radiation therapy may increase metastatic potential in alveolar rhabdomyosarcoma. Pediatr Blood Cancer 62(9):1550–1554. doi:10.1002/pbc.25516 CrossRefPubMed

77.

Kim MP, Evans DB, Wang H et al (2009) Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 4(11):1670–1680. doi:10.1038/nprot.2009.171 CrossRefPubMedPubMedCentral

78.

MacDonald TJ, Taga T, Shimada H et al (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48(1):151–157PubMed

79.

MacDonald TJ, Vezina G, Stewart CF et al (2013) Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro-oncology 15(10):1438–1444. doi:10.1093/neuonc/not058 CrossRefPubMedPubMedCentral

80.

Wan X, Yeung C, Heske C et al (2015) IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma. Neoplasia 17(4):358–366. doi:10.1016/j.neo.2015.03.001 CrossRefPubMedPubMedCentral

81.

Stewart E, Goshorn R, Bradley C et al (2014) Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep 9(3):829–841. doi:10.1016/j.celrep.2014.09.028 CrossRefPubMedPubMedCentral

82.

Knowles BB, McCarrick J, Fox N et al (1990) Osteosarcomas in transgenic mice expressing an alpha-amylase-SV40 T-antigen hybrid gene. Am J Pathol 137(2):259–262PubMedPubMedCentral

83.

Zanola A, Rossi S, Faggi F et al (2012) Rhabdomyosarcomas: an overview on the experimental animal models. J Cell Mol Med 16(7):1377–1391. doi:10.1111/j.1582-4934.2011.01518.x CrossRefPubMedPubMedCentral

84.

Post SM (2012) Mouse models of sarcomas: critical tools in our understanding of the pathobiology. Clin Sarcoma Res 2(1):20. doi:10.1186/2045-3329-2-20 CrossRefPubMedPubMedCentral

85.

Ng AJ, Mutsaers AJ, Baker EK et al (2012) Genetically engineered mouse models and human osteosarcoma. Clin Sarcoma Res 2(1):19. doi:10.1186/2045-3329-2-19 CrossRefPubMedPubMedCentral

86.

Dodd RD, Mito JK, Kirsch DG (2010) Animal models of soft-tissue sarcoma. Disease Models Mech 3(9–10):557–566. doi:10.1242/dmm.005223 CrossRef

87.

Cook GJ, Pardee TS (2013) Animal models of leukemia: any closer to the real thing? Cancer Metastasis Rev 32(1–2):63–76. doi:10.1007/s10555-012-9405-5 CrossRefPubMedPubMedCentral

88.

Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34):4702–4711. doi:10.1038/onc.2008.109 CrossRefPubMedPubMedCentral

89.

Weiss WA, Aldape K, Mohapatra G et al (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16(11):2985–2995. doi:10.1093/emboj/16.11.2985 CrossRefPubMedPubMedCentral

90.

Rounbehler RJ, Li W, Hall MA et al (2009) Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 69(2):547–553. doi:10.1158/0008-5472.CAN-08-2968 CrossRefPubMedPubMedCentral

91.

Haber M, Murray J, Carnegie-Clark A et al. (2012) Anticancer compound curaxin CBL0137, that simultaneously suppresses NF-κB and activates p53, is highly effective in two independent mouse models of neuroblastoma. Proc AACR 104 (2759A)

92.

Lock R, Carol H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Purmal A, Gudkov A, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA (2016) Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. (submitted)

93.

Puissant A, Frumm SM, Alexe G et al (2013) Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 3(3):308–323. doi:10.1158/2159-8290.CD-12-0418 CrossRefPubMedPubMedCentral

94.

Romer JT, Kimura H, Magdaleno S et al (2004) Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(±)p53(−/−) mice. Cancer Cell 6(3):229–240. doi:10.1016/j.ccr.2004.08.019 CrossRefPubMed

95.

Keller C, Arenkiel BR, Coffin CM et al (2004) Alveolar rhabdomyosarcomas in conditional Pax3: Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 18(21):2614–2626. doi:10.1101/gad.1244004 CrossRefPubMedPubMedCentral

96.

Abraham J, Nelon LD, Kubicek CB et al (2011) Preclinical testing of erlotinib in a transgenic alveolar rhabdomyosarcoma mouse model. Sarcoma 2011:130484. doi:10.1155/2011/130484 CrossRefPubMedPubMedCentral

97.

98.

Kool M, Koster J, Bunt J et al (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 3(8):e3088. doi:10.1371/journal.pone.0003088 CrossRefPubMedPubMedCentral

Title: Identifying novel therapeutic agents using xenograft models of pediatric cancer
Authors: Raushan T. Kurmasheva
Peter J. Houghton
Publication date: 01-08-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-3042-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer

Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer

High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer

Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors

Population pharmacokinetics of bevacizumab in cancer patients with external validation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer